GlassScriptPhysician profile
Thomas L Shoaf
NPI 1396031027
$43,562.50
in general payments reported to CMS, 2019-2025
40 companies · $30K in 2025
The $30K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $1,098 · 2021: $4,432 · 2022: $2,803 · 2023: $2,619 · 2024: $1,941 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $27K · Food and Beverage: $7,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $27,090.00 |
| Food and Beverage | $7,445.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $27,311.78 | 2019-2025 | Neurostar Tms Therapy System |
| Validus Pharmaceuticals LLC | $3,489.45 | 2019-2025 | Equetro, Equetro, Raldesy |
| Abbvie INC. | $1,627.07 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,065.59 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $966.71 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $940.14 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $891.90 | 2020-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $880.99 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $755.04 | 2021-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $737.10 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $515.31 | 2020-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $452.75 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $424.19 | 2019-2025 | Rexulti, Brintellix |
| Allergan, INC. | $381.60 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $381.14 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $227.32 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $222.15 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $219.88 | 2019-2022 | |
| Almatica Pharma LLC | $211.02 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $206.96 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $205.06 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.39 | 2020-2025 | Trintellix |
| Alfasigma USA, INC. | $140.70 | 2021-2022 | |
| Eisai INC. | $127.08 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $123.51 | 2020-2021 | |
| Harmony Biosciences LLC | $122.48 | 2022-2024 | Wakix |
| Bausch Health US, LLC | $110.76 | 2019-2024 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $102.31 | 2022-2025 | Auvelity |
| Noven Therapeutics, LLC | $100.35 | 2020-2023 | Secuado |
| Adlon Therapeutics L.P. | $74.58 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $64.71 | 2023-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $58.70 | 2019-2025 | Relexxii |
| Medline Industries LP | $44.72 | 2025 | |
| Arbor Pharmaceuticals, INC. | $41.14 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $35.56 | 2020-2021 | |
| Shire North American Group INC | $32.61 | 2019 | |
| Collegium Pharmaceutical, INC. | $32.25 | 2025 | Jornay Pm |
| Tonix Medicines, INC. | $18.71 | 2025 | Tonmya |
| Pfizer INC. | $15.91 | 2025 | |
| Currax Pharmaceuticals LLC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Shoaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.